Release Date: 28/02/11 11:35 Summary: Interim Results 2011 Price Sensitive: Yes Download Document 1.91MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%